|
humans |
51 |
|
adult |
42 |
|
female |
35 |
|
male |
34 |
|
middle aged |
34 |
|
kidney transplantation |
29 |
|
lupus nephritis |
28 |
|
peritoneal dialysis |
26 |
|
systemic lupus erythematosus |
23 |
|
aged |
20 |
|
asian continental ancestry group - genetics |
20 |
|
sle |
20 |
|
dialysis |
19 |
|
chronic kidney disease |
18 |
|
follow-up studies |
17 |
|
genetic predisposition to disease |
17 |
|
genome-wide association study |
17 |
|
risk factors |
17 |
|
time factors |
17 |
|
hong kong - epidemiology |
16 |
|
animals |
15 |
|
chinese |
15 |
|
immunocompromised host |
15 |
|
immunosuppressive agents - therapeutic use |
15 |
|
asian |
14 |
|
association |
14 |
|
hepatitis b |
14 |
|
hong kong |
14 |
|
lupus erythematosus, systemic - genetics |
13 |
|
peritonitis |
13 |
|
prevalence |
13 |
|
prognosis |
13 |
|
renal transplantation |
13 |
|
transplantation, homologous |
13 |
|
acute kidney injury |
12 |
|
case-control studies |
12 |
|
cells, cultured |
12 |
|
ephrin-a2 - genetics |
12 |
|
epidemiology |
12 |
|
fibrosis |
12 |
|
genotype |
12 |
|
outcome |
12 |
|
proteinuria |
12 |
|
retrospective studies |
12 |
|
risk assessment |
12 |
|
uhrf1bp1 |
12 |
|
anti-bacterial agents - therapeutic use |
11 |
|
antibodies, antinuclear - blood |
11 |
|
antigens, cd3 - genetics |
11 |
|
autoantibodies |
11 |
|
autoantibodies - blood |
11 |
|
cd247 |
11 |
|
cohort studies |
11 |
|
gwas |
11 |
|
inflammation |
11 |
|
lupus erythematosus, systemic - genetics - immunology |
11 |
|
treatment outcome |
11 |
|
adolescent |
10 |
|
glomerulonephritis |
10 |
|
hyaluronan |
10 |
|
intracellular signaling peptides and proteins - genetics |
10 |
|
intradermal |
10 |
|
kidney transplantation - adverse effects |
10 |
|
lupus erythematosus, systemic - enzymology - genetics |
10 |
|
prospective studies |
10 |
|
severity of illness index |
10 |
|
china |
9 |
|
combined modality therapy |
9 |
|
covid-19 |
9 |
|
dna, viral - blood |
9 |
|
drug therapy, combination |
9 |
|
infection |
9 |
|
kidney failure, chronic - therapy |
9 |
|
medical sciences |
9 |
|
nephrotic syndrome |
9 |
|
outcomes |
9 |
|
anti-dsdna antibodies |
8 |
|
antiviral |
8 |
|
ascitic fluid |
8 |
|
azathioprine - therapeutic use |
8 |
|
biomarkers |
8 |
|
carcinoma/metabolism |
8 |
|
carcinoma/secondary |
8 |
|
cell adhesion |
8 |
|
chemicals and cas registry numbers |
8 |
|
creatinine - blood |
8 |
|
cyclophosphamide |
8 |
|
cyclosporine - therapeutic use |
8 |
|
glucose - pharmacology |
8 |
|
hbv |
8 |
|
hepatitis b vaccination |
8 |
|
iga nephropathy |
8 |
|
il-17 |
8 |
|
immunosuppression |
8 |
|
kidney - pathology |
8 |
|
lupus erythematosus |
8 |
|
model |
8 |
|
mycophenolate mofetil |
8 |
|
nephritis |
8 |
|
nephrotoxicity |
8 |
|
nucleoside analogues |
8 |
|
peritoneal dialysis - adverse effects |
8 |
|
peritoneal mesothelial cells |
8 |
|
prediction |
8 |
|
prednisolone - therapeutic use |
8 |
|
renal failure |
8 |
|
rna, viral - analysis |
8 |
|
tacrolimus |
8 |
|
tacrolimus - therapeutic use |
8 |
|
tenofovir |
8 |
|
tlr7 agonist |
8 |
|
acute disease |
7 |
|
advanced cirrhosis |
7 |
|
antigens, cd11b - genetics |
7 |
|
asian continental ancestry group - ethnology - genetics |
7 |
|
chronic disease |
7 |
|
cluster analysis |
7 |
|
cytokines |
7 |
|
debridement |
7 |
|
disease susceptibility |
7 |
|
epistasis |
7 |
|
ets1 |
7 |
|
fatal outcome |
7 |
|
hepatitis |
7 |
|
hepatitis - diagnosis - etiology |
7 |
|
hepatorenal syndrome |
7 |
|
immunogenicity |
7 |
|
immunosuppressive agents - adverse effects - therapeutic use |
7 |
|
interstitial fibrosis |
7 |
|
lupus erythematosus, systemic - complications |
7 |
|
lupus erythematosus, systemic - ethnology - genetics |
7 |
|
lupus erythematosus, systemic - ethnology - immunology |
7 |
|
mesothelial cells |
7 |
|
multivariate analysis |
7 |
|
nephritis - ethnology - genetics |
7 |
|
ovarian cancer |
7 |
|
peritoneal dialysis, continuous ambulatory |
7 |
|
peritoneum |
7 |
|
prednisolone - adverse effects - therapeutic use |
7 |
|
recurrence |
7 |
|
relapse |
7 |
|
renal transplant |
7 |
|
systemic |
7 |
|
treatment |
7 |
|
up-regulation - drug effects |
7 |
|
urology and nephrology |
7 |
|
alanine transaminase - blood |
6 |
|
amino acid |
6 |
|
antibodies - pharmacology |
6 |
|
asian continental ancestry group |
6 |
|
azathioprine |
6 |
|
base sequence |
6 |
|
burkholderia cepacia |
6 |
|
capd |
6 |
|
cardiovascular diseases |
6 |
|
china - ethnology |
6 |
|
chronic allograft nephropathy |
6 |
|
complement |
6 |
|
cross-sectional studies |
6 |
|
decorin |
6 |
|
diagnosis, differential |
6 |
|
dose-response relationship, drug |
6 |
|
dyslipidaemia |
6 |
|
economic burden |
6 |
|
electrophysiology |
6 |
|
end-stage renal disease |
6 |
|
epithelial cells - drug effects - metabolism |
6 |
|
estimated glomerular filtration rate |
6 |
|
fibronectin |
6 |
|
flow cytometry |
6 |
|
gene expression |
6 |
|
glomerular filtration rate |
6 |
|
glomerulonephritis, iga - metabolism - pathology |
6 |
|
hemodialysis |
6 |
|
hepatitis b surface antigens - blood |
6 |
|
immunoglobulin a - metabolism |
6 |
|
immunohistochemistry |
6 |
|
immunosuppressive agents |
6 |
|
immunosuppressive agents - adverse effects |
6 |
|
kaplan-meier estimate |
6 |
|
kidney inflammation |
6 |
|
kidney transplantation - immunology |
6 |
|
lamivudine - therapeutic use |
6 |
|
linkage disequilibrium |
6 |
|
long-term |
6 |
|
membranous nephropathy |
6 |
|
mycophenolic acid |
6 |
|
nerve tissue proteins - genetics |
6 |
|
nocturnal home haemodialysis |
6 |
|
peritoneal dialysis - methods |
6 |
|
peritoneal dialysis, continuous ambulatory - adverse effects |
6 |
|
peritoneum - cytology |
6 |
|
peritonitis - drug therapy - microbiology |
6 |
|
polymorphism, single nucleotide - genetics |
6 |
|
predictive value of tests |
6 |
|
protein-serine-threonine kinases - genetics |
6 |
|
proximal renal tubular epithelial cells |
6 |
|
quality of life |
6 |
|
renal dysfunction |
6 |
|
reverse transcriptase polymerase chain reaction |
6 |
|
safety |
6 |
|
stat4 transcription factor - genetics |
6 |
|
survival rate |
6 |
|
syndecan-1 |
6 |
|
thrombomodulin |
6 |
|
transferrin |
6 |
|
ultrasound |
6 |
|
valvular heart disease |
6 |
|
1-phosphatidylinositol 3-kinase - antagonists & inhibitors - metabolism |
5 |
|
administration, oral |
5 |
|
age factors |
5 |
|
aged, 80 and over |
5 |
|
anaerobic bacteria |
5 |
|
antifungal agents - therapeutic use |
5 |
|
antitubercular agents - therapeutic use |
5 |
|
antiviral agents - adverse effects - therapeutic use |
5 |
|
atrial fibrillation |
5 |
|
biopsy |
5 |
|
bone marrow transplantation - immunology |
5 |
|
candida - classification |
5 |
|
cardiovascular diseases - mortality |
5 |
|
catheters, indwelling |
5 |
|
cell line |
5 |
|
complication |
5 |
|
continuous ambulatory peritoneal dialysis |
5 |
|
corticosteroid |
5 |
|
cyclophosphamide - therapeutic use |
5 |
|
cytomegalovirus - genetics - immunology - pathogenicity |
5 |
|
cytomegalovirus infections - immunology - virology |
5 |
|
dental plaque - microbiology |
5 |
|
dialysis initiation |
5 |
|
dmf index |
5 |
|
dna, viral - analysis |
5 |
|
end‐stage renal disease |
5 |
|
enterobacteriaceae - classification |
5 |
|
epithelial cells - metabolism |
5 |
|
exons |
5 |
|
gingival overgrowth |
5 |
|
gingival overgrowth - chemically induced - classification |
5 |
|
gingival overgrowth - chemically induced - complications - microbiology |
5 |
|
glomerular mesangium - cytology - metabolism |
5 |
|
glucocorticoids - therapeutic use |
5 |
|
glucose |
5 |
|
glucose degradation products |
5 |
|
graft rejection |
5 |
|
gram-negative aerobic rods and cocci - classification |
5 |
|
gram-negative facultatively anaerobic rods - classification |
5 |
|
haemodialysis |
5 |
|
health status |
5 |
|
hepatitis b - complications - drug therapy |
5 |
|
hepatitis c |
5 |
|
herpes zoster |
5 |
|
hyaluronic acid - biosynthesis - blood - metabolism |
5 |
|
hypernatraemia |
5 |
|
immunoglobulin light chains - analysis |
5 |
|
in situ hybridization |
5 |
|
incidence |
5 |
|
influenza |
5 |
|
interleukin-8 - biosynthesis - genetics |
5 |
|
invasive pneumococcal disease |
5 |
|
ischaemic stroke |
5 |
|
kidney failure, chronic - complications - mortality - physiopathology - therapy |
5 |
|
kidney tubules, proximal - drug effects - immunology - injuries - metabolism |
5 |
|
lamivudine |
5 |
|
living donors |
5 |
|
lung abscess |
5 |
|
lupus |
5 |
|
lupus erythematosus, systemic - complications - drug therapy |
5 |
|
lupus nephritis - drug therapy |
5 |
|
mannitol - pharmacology |
5 |
|
membranous lupus nephritis |
5 |
|
mouth - microbiology |
5 |
|
mycobacterium |
5 |
|
mycobacterium infections, atypical - complications - diagnosis |
5 |
|
mycophenolic acid - adverse effects - analogs & derivatives - therapeutic use |
5 |
|
nf-kappa b - antagonists & inhibitors - metabolism |
5 |
|
opportunistic infections - complications - diagnosis |
5 |
|
opportunistic infections - immunology - virology |
5 |
|
oral health |
5 |
|
pathogenesis |
5 |
|
patient‐reported outcome |
5 |
|
periodontal diseases |
5 |
|
periodontal diseases - therapy |
5 |
|
periodontal index |
5 |
|
periodontitis - complications - microbiology |
5 |
|
peritoneal cavity - cytology |
5 |
|
pharmacokinetics |
5 |
|
polymerase chain reaction |
5 |
|
polymerase chain reaction - methods |
5 |
|
polymorphism, genetic |
5 |
|
postoperative complications - virology |
5 |
|
pregnancy |
5 |
|
proteinuria - drug therapy - etiology |
5 |
|
proximal tubular epithelial cells |
5 |
|
reactive oxygen species - metabolism |
5 |
|
renal dialysis |
5 |
|
renal palliative care |
5 |
|
rhodococcus equi |
5 |
|
rna, messenger - metabolism |
5 |
|
sensitivity and specificity |
5 |
|
shock, septic - etiology |
5 |
|
sirolimus |
5 |
|
sodium |
5 |
|
statistics as topic |
5 |
|
survival |
5 |
|
synovitis |
5 |
|
tomography, x-ray computed |
5 |
|
transplantation |
5 |
|
treatment refusal |
5 |
|
tricuspid annuloplasty |
5 |
|
tuberculosis |
5 |
|
uraemic symptoms |
5 |
|
uremia - etiology |
5 |
|
vascular endothelial growth factor |
5 |
|
vasculitis |
5 |
|
viral envelope proteins - genetics - immunology |
5 |
|
zonula occludens protein 1 |
5 |
|
3d culture |
4 |
|
abdominal pain - microbiology |
4 |
|
actinomycetales infections - complications - diagnosis - therapy |
4 |
|
acute renal failure |
4 |
|
adenine - analogs and derivatives - therapeutic use |
4 |
|
adhesion |
4 |
|
advanced glycation end-products |
4 |
|
aeromonas - isolation & purification |
4 |
|
alanine transaminase - metabolism |
4 |
|
albumin |
4 |
|
alopecia - chemically induced |
4 |
|
alpha-fetoproteins - analysis |
4 |
|
alpha-galactosidase - genetics |
4 |
|
angiography - adverse effects - economics - methods |
4 |
|
angioplasty, balloon |
4 |
|
angiotensin-converting enzyme inhibitors - therapeutic use |
4 |
|
anionic charge |
4 |
|
anti-bacterial agents |
4 |
|
anti-diabetic agents |
4 |
|
anti-hypertensive |
4 |
|
anti-inflammatory agents - administration & dosage - adverse effects |
4 |
|
antibiotic prophylaxis |
4 |
|
antilymphocyte serum - therapeutic use |
4 |
|
antiphospholipid antibodies |
4 |
|
aqp-3 |
4 |
|
aquaporin 1 |
4 |
|
aquaporin 1 (aqp1) |
4 |
|
aquaporin 3 |
4 |
|
aquaporin 3 (aqp3) |
4 |
|
aquaporins - analysis - genetics |
4 |
|
aquaporins - genetics - metabolism |
4 |
|
arthritis, infectious - etiology |
4 |
|
arthritis, rheumatoid - complications - drug therapy |
4 |
|
arthroplasty, replacement, hip |
4 |
|
azathioprine - administration & dosage - adverse effects |
4 |
|
binding sites |
4 |
|
biocompatibility |
4 |
|
bioengineering |
4 |
|
biomarker |
4 |
|
blood group antigens |
4 |
|
blood pressure - drug effects |
4 |
|
cadaver |
4 |
|
calcitriol |
4 |
|
carbon radioisotopes - diagnostic use |
4 |
|
carcinoma, hepatocellular - diagnosis - etiology - surgery |
4 |
|
carrier state |
4 |
|
catheterization, central venous - instrumentation |
4 |
|
cell culture techniques - methods |
4 |
|
cell injury |
4 |
|
cell membrane permeability - drug effects |
4 |
|
cell proliferation |
4 |
|
cera |
4 |
|
charge dependent iga binding |
4 |
|
chemokine |
4 |
|
chemokines - genetics |
4 |
|
chromatography, ion exchange |
4 |
|
chromosome banding |
4 |
|
chromosomes, human, x |
4 |
|
chronic kidney failure |
4 |
|
ciclosporin a |
4 |
|
co-culture |
4 |
|
complications of hbv reactivation |
4 |
|
continuous ambulatory peritoneal dialysis (capd) |
4 |
|
conventional arteriogram |
4 |
|
cost |
4 |
|
cost-effectiveness |
4 |
|
cross infection - transmission |
4 |
|
ct angiogram |
4 |
|
culture media, conditioned - pharmacology |
4 |
|
cyclin-dependent kinase inhibitor p21 - biosynthesis - genetics |
4 |
|
cyclophosphamide - administration & dosage - adverse effects |
4 |
|
cyclophosphamide - adverse effects - therapeutic use |
4 |
|
cyclosporine - blood - therapeutic use |
4 |
|
cytomegalovirus infections - epidemiology |
4 |
|
deposits of iga |
4 |
|
diabetes mellitus |
4 |
|
dialysis solutions - pharmacology |
4 |
|
disease outbreaks |
4 |
|
disease transmission, infectious |
4 |
|
disseminated intravascular coagulation - etiology |
4 |
|
diuretics, osmotic - pharmacology |
4 |
|
dna primers |
4 |
|
dna primers - genetics |
4 |
|
dna, complementary - analysis |
4 |
|
drainage - methods |
4 |
|
drug interactions |
4 |
|
drug resistance, multiple, bacterial |
4 |
|
drug resistance, viral |
4 |
|
drug therapy, combination - therapeutic use |
4 |
|
end stage renal disease |
4 |
|
endothelial cells |
4 |
|
entecavir |
4 |
|
enterococcus peritonitis |
4 |
|
enzyme-linked immunosorbent assay |
4 |
|
epithelial cells - chemistry - cytology - physiology |
4 |
|
epithelial cells - immunology - metabolism |
4 |
|
epstein-barr virus |
4 |
|
esa |
4 |
|
extrahepatic manifestation of hbv |
4 |
|
fabry disease - enzymology - genetics - physiopathology |
4 |
|
fabry's disease |
4 |
|
fasciitis, necrotizing - diagnosis - etiology - therapy |
4 |
|
fasciitis, necrotizing - drug therapy - etiology - surgery |
4 |
|
fatigue |
4 |
|
femur head necrosis - chemically induced - surgery |
4 |
|
fishes - microbiology |
4 |
|
gene expression - drug effects |
4 |
|
gene expression regulation - immunology |
4 |
|
genetic mutation |
4 |
|
glomerular mesangial cell |
4 |
|
glomerular mesangium - cytology - immunology - metabolism |
4 |
|
glomerular mesangium - metabolism - pathology |
4 |
|
glomerulonephritis, iga - metabolism |
4 |
|
glomerulonephritis, membranous - drug therapy |
4 |
|
glycerol - pharmacokinetics |
4 |
|
glycosylation |
4 |
|
graft rejection - blood - prevention & control |
4 |
|
gram-negative bacterial infections - drug therapy - etiology - surgery |
4 |
|
gram-positive bacterial infections - drug therapy - etiology |
4 |
|
granulomatous interstitial nephritis |
4 |
|
haplotype |
4 |
|
haplotypes |
4 |
|
hepacivirus - isolation & purification |
4 |
|
hepatitis b infection |
4 |
|
hepatitis b virus |
4 |
|
hepatitis b, chronic - complications |
4 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy - mortality |
4 |
|
hepatocellular carcinoma |
4 |
|
herpes zoster - chemically induced |
4 |
|
herpesvirus 4, human - isolation & purification |
4 |
|
heterozygote detection |
4 |
|
high mortality of acute pancreatitis |
4 |
|
hospital units - organization & administration |
4 |
|
hospitalization |
4 |
|
human peritoneal mesothelial cell |
4 |
|
icodextrin |
4 |
|
iga1 |
4 |
|
immunoblotting |
4 |
|
immunocompromised hosts, β-haemolytic streptococcus |
4 |
|
immunoenzyme techniques |
4 |
|
immunoglobulin a (iga) nephropathy |
4 |
|
immunosuppression - adverse effects |
4 |
|
immunosuppressive agents - administration & dosage - adverse effects |
4 |
|
immunosuppressive agents - blood - therapeutic use |
4 |
|
immunosuppressive agents - pharmacology |
4 |
|
insulin-independent |
4 |
|
intercellular adhesion molecule-1 |
4 |
|
interferon |
4 |
|
interferon regulatory factors - genetics |
4 |
|
interleukin-6 - blood |
4 |
|
ischemia-reperfusion injury |
4 |
|
isoniazid - therapeutic use |
4 |
|
issue 120 |
4 |
|
ivig |
4 |
|
kidney |
4 |
|
kidney - immunology - pathology |
4 |
|
kidney - metabolism - pathology |
4 |
|
kidney diseases - blood - drug therapy - therapy |
4 |
|
kidney diseases - complications - surgery |
4 |
|
kidney diseases - diagnosis - etiology - pathology |
4 |
|
kidney diseases - drug therapy - therapy |
4 |
|
kidney failure, chronic - diagnosis - surgery |
4 |
|
kidney failure, chronic - etiology - surgery |
4 |
|
kidney failure, chronic - mortality - therapy |
4 |
|
kidney failure, chronic - pathology - therapy |
4 |
|
kidney mesangial cells |
4 |
|
kidney transplantation - adverse effects - methods |
4 |
|
kidney transplantation - adverse effects - mortality |
4 |
|
kidney transplantation - immunology - physiology |
4 |
|
kidney transplantation - pathology |
4 |
|
kidney transplantation - physiology |
4 |
|
kidney tubules - cytology |
4 |
|
kidney tubules, proximal - cytology - immunology - metabolism |
4 |
|
lectins - metabolism |
4 |
|
lipoproteins |
4 |
|
liver neoplasms - diagnosis - etiology - surgery |
4 |
|
living kidney donor |
4 |
|
ln |
4 |
|
long term |
4 |
|
lung abscess - complications - diagnosis - therapy |
4 |
|
lupus erythematosus, systemic - blood - genetics |
4 |
|
lupus nephritis - complications - drug therapy - virology |
4 |
|
lymphoma |
4 |
|
lymphoma, b-cell - chemistry - etiology - genetics |
4 |
|
macrophages |
4 |
|
malnutrition - etiology |
4 |
|
membranous glomerulonephritis |
4 |
|
mesangial cells |
4 |
|
metastasis |
4 |
|
mice |
4 |
|
mice, inbred balb c |
4 |
|
micro-costing |
4 |
|
microfluidics |
4 |
|
minimization |
4 |
|
morbidity |
4 |
|
mortality |
4 |
|
multicellular spheroids |
4 |
|
mycoses - diagnosis - drug therapy |
4 |
|
necrotizing fasciitis |
4 |
|
nephritis, interstitial - complications - drug therapy - pathology |
4 |
|
nephritis, interstitial - immunology - physiopathology |
4 |
|
nephrotic syndrome - complications - drug therapy |
4 |
|
nephrotic syndrome - drug therapy |
4 |
|
osmolality |
4 |
|
p-cadherin |
4 |
|
p21 |
4 |
|
p70 s6 kinase |
4 |
|
p70s6k |
4 |
|
pancreatitis - diagnosis - etiology |
4 |
|
parvoviridae infections - transmission |
4 |
|
parvovirus b19, human |
4 |
|
pedigree |
4 |
|
peritoneal adhesion |
4 |
|
peritoneal dialysis first |
4 |
|
peritoneal dialysis peritoneal mesothelial cells |
4 |
|
peritoneal inflammation |
4 |
|
peritoneum - drug effects - metabolism |
4 |
|
peritoneum - physiopathology |
4 |
|
peritonitis - drug therapy - epidemiology - microbiology |
4 |
|
peritonitis - microbiology |
4 |
|
pilot projects |
4 |
|
piperacillin - therapeutic use |
4 |
|
platelet-derived growth factor - immunology - secretion |
4 |
|
polycation |
4 |
|
polymeric iga |
4 |
|
polymers - metabolism |
4 |
|
polymorphism, single nucleotide |
4 |
|
portal vein - radiography |
4 |
|
post- transplantation |
4 |
|
postoperative period |
4 |
|
prednisone - administration & dosage - adverse effects |
4 |
|
proteinuria - immunology - metabolism |
4 |
|
pseudomonas infections - drug therapy - etiology - surgery |
4 |
|
radiography, thoracic |
4 |
|
rapamycin |
4 |
|
receptor |
4 |
|
recombinant proteins |
4 |
|
regression analysis |
4 |
|
renal |
4 |
|
renal anemia |
4 |
|
renal dialysis - adverse effects |
4 |
|
renal dialysis - instrumentation - methods |
4 |
|
renal insufficiency - etiology |
4 |
|
renal replacement therapy |
4 |
|
reperfusion injury - pathology |
4 |
|
resistance |
4 |
|
respiratory tract infections - chemically induced |
4 |
|
rhodococcus - isolation & purification |
4 |
|
rna, messenger - analysis |
4 |
|
rna, messenger - genetics - metabolism |
4 |
|
scleroderma, diffuse - complications - drug therapy |
4 |
|
secondary syphilis |
4 |
|
serum albumin |
4 |
|
serum albumin - analysis |
4 |
|
shear stress |
4 |
|
shock, septic - diagnosis - etiology - therapy |
4 |
|
sialylation |
4 |
|
single nucleotide polymorphism |
4 |
|
sirolimus - pharmacology |
4 |
|
skin - injuries |
4 |
|
skin transplantation |
4 |
|
sodium–glucose co-transporter type 2 inhibitors |
4 |
|
steroid |
4 |
|
streptococcal infections - drug therapy - etiology - surgery |
4 |
|
streptococcal infections - epidemiology - microbiology |
4 |
|
streptococcus bovis |
4 |
|
streptococcus bovis - isolation & purification |
4 |
|
streptococcus pyogenes |
4 |
|
superior mesenteric artery syndrome |
4 |
|
superior mesenteric artery syndrome - etiology - radiography - therapy |
4 |
|
surgical wound infection - etiology |
4 |
|
survival rate - trends |
4 |
|
susceptibility |
4 |
|
syphilis - complications - diagnosis - pathology |
4 |
|
syphilis, cutaneous - complications - diagnosis |
4 |
|
tacrolimus - blood - therapeutic use |
4 |
|
tacrolimus conversion |
4 |
|
three pore model |
4 |
|
tissue donors |
4 |
|
tomography, x-ray computed - adverse effects - economics - methods |
4 |
|
transferrin - pharmacology |
4 |
|
tubular cells |
4 |
|
tubuloglomerular cross talk |
4 |
|
type 2 diabetes mellitus |
4 |
|
ultrasmall pores |
4 |
|
up-regulation |
4 |
|
up-regulation - drug effects - immunology |
4 |
|
urinary tract infections - chemically induced |
4 |
|
vaccine |
4 |
|
vascular anomalies |
4 |
|
vascular cell adhesion molecule-1 |
4 |
|
water channel |
4 |
|
wedge resection |
4 |
|
weight loss |
4 |
|
y chromosome |
4 |
|
α-galactosidase a |
4 |
|
β1 integrin |
4 |
|
γ-iga |
4 |
|
2-aminopurine - analogs & derivatives - therapeutic use |
3 |
|
acquired cystic kidney disease |
3 |
|
actinomycetales infections - drug therapy - microbiology - radiography |
3 |
|
actuarial analysis |
3 |
|
acute kidney injury - chemically induced - complications |
3 |
|
acute kidney injury - chemically induced - pathology |
3 |
|
acute kidney injury - immunology - pathology |
3 |
|
adenine - analogs & derivatives - pharmacology - therapeutic use |
3 |
|
adequacy |
3 |
|
adiponectin - blood |
3 |
|
adrenal cortex hormones - administration & dosage - adverse effects |
3 |
|
adrenal cortex hormones - therapeutic use |
3 |
|
age distribution |
3 |
|
age of onset |
3 |
|
aki |
3 |
|
albuminuria - chemically induced - drug therapy - immunology |
3 |
|
albuminuria - drug therapy |
3 |
|
alcaligenes |
3 |
|
alcaligenes xylosoxidans |
3 |
|
allograft |
3 |
|
amphotericin b - therapeutic use |
3 |
|
analysis of variance |
3 |
|
angiography |
3 |
|
angiography - economics - methods |
3 |
|
angiotensin receptor antagonists |
3 |
|
angiotensin receptor blocker (arb) |
3 |
|
angiotensin-converting enzyme inhibitor (acei) |
3 |
|
anthraquinone |
3 |
|
anthraquinones - adverse effects |
3 |
|
anti-bacterial agents - adverse effects - pharmacokinetics |
3 |
|
anti-glomerular basement membrane disease - blood - complications - drug therapy - enzymology |
3 |
|
anti-glomerular basement membrane disease - complications - epidemiology - ethnology |
3 |
|
anti-histone antibodies |
3 |
|
anti-infective agents - administration & dosage - adverse effects |
3 |
|
anti-inflammatory agents, non-steroidal - adverse effects |
3 |
|
anti-neutrophil cytoplasm auto-antibody (anca) |
3 |
|
anti-nucleohistone antibodies |
3 |
|
anti-obesity agents - antagonists & inhibitors |
3 |
|
antibiotics, antineoplastic - toxicity |
3 |
|
antibodies - analysis - immunology |
3 |
|
antibodies - blood |
3 |
|
antibodies, antineutrophil cytoplasmic - analysis - immunology |
3 |
|
antibodies, antineutrophil cytoplasmic - blood - metabolism |
3 |
|
antibodies, antinuclear - immunology |
3 |
|
anticholesteremic agents - administration & dosage |
3 |
|
antifungal agents |
3 |
|
antigens, cd |
3 |
|
antigens, cd - genetics - immunology - metabolism |
3 |
|
antigens, surface - genetics |
3 |
|
antiglomerular basement membrane antibody disease |
3 |
|
antihypertensive agents - therapeutic use |
3 |
|
antiviral agents - administration & dosage - adverse effects - therapeutic use |
3 |
|
antiviral agents - therapeutic use |
3 |
|
anuria - mortality - physiopathology - therapy |
3 |
|
anxiety |
3 |
|
apoproteins - pharmacology |
3 |
|
apoptosis regulatory proteins |
3 |
|
appendicitis - complications - diagnosis |
3 |
|
arthritis, rheumatoid - ethnology - genetics |
3 |
|
ascites - etiology - therapy |
3 |
|
ascitic fluid - metabolism |
3 |
|
asia |
3 |
|
asialoglycoprotein receptor |
3 |
|
autoimmunity |
3 |
|
b cell depletion |
3 |
|
b cell signatures |
3 |
|
b cells |
3 |
|
bacterial infections - etiology - metabolism |
3 |
|
basement membrane - chemistry - immunology |
3 |
|
basic fibroblast growth factor (fgf) |
3 |
|
beta-lactamases - biosynthesis |
3 |
|
biological markers - blood |
3 |
|
biological transport, active |
3 |
|
biopsy, needle - adverse effects - methods |
3 |
|
blood pressure |
3 |
|
blotting, western |
3 |
|
body weight |
3 |
|
bone density - drug effects |
3 |
|
bone density - drug effects - physiology |
3 |
|
bone diseases, metabolic - chemically induced - drug therapy - etiology |
3 |
|
bone marrow transplantation - adverse effects |
3 |
|
bone mineral density |
3 |
|
brain - microbiology |
3 |
|
burkholderia cepacia - drug effects - isolation & purification |
3 |
|
burkholderia infections - etiology - microbiology - therapy |
3 |
|
c-reactive protein |
3 |
|
c-reactive protein - analysis |
3 |
|
c-reactive protein - analysis - metabolism |
3 |
|
c-reactive protein - metabolism |
3 |
|
calcitonin - blood - metabolism |
3 |
|
calcitriol - administration & dosage |
3 |
|
calcitriol - therapeutic use |
3 |
|
calcium |
3 |
|
calcium - blood |
3 |
|
calcium - urine |
3 |
|
calcium channel agonists - therapeutic use |
3 |
|
cancer nanomedicine |
3 |
|
cancer stem cells |
3 |
|
carcinoma, hepatocellular - therapy |
3 |
|
cardiovascular |
3 |
|
caregiver burden |
3 |
|
carrier proteins - genetics |
3 |
|
carrier state - diagnosis - virology |
3 |
|
catheters, indwelling - adverse effects |
3 |
|
cd44 |
3 |
|
cell division |
3 |
|
cell proliferation - drug effects |
3 |
|
cell survival - drug effects |
3 |
|
cell viability |
3 |
|
cephalosporin |
3 |
|
chemokine ccl2 - biosynthesis - genetics |
3 |
|
chemokine ccl5 - genetics |
3 |
|
chemokine ccl5 - metabolism |
3 |
|
chemoprophylaxis |
3 |
|
china - epidemiology |
3 |
|
chinese subjects |
3 |
|
chlorambucil - therapeutic use |
3 |
|
cholestasis - drug therapy |
3 |
|
chronic renal failure (crf) |
3 |
|
chronic viral hepatitis |
3 |
|
chronotropic incompetence |
3 |
|
ciprofloxacin - administration & dosage - adverse effects |
3 |
|
clarithromycin - adverse effects - pharmacokinetics |
3 |
|
classical memory b cells |
3 |
|
cognitive impairment |
3 |
|
collagen type i - genetics |
3 |
|
colonoscopy |
3 |
|
colonoscopy - adverse effects |
3 |
|
coloring agents |
3 |
|
combined antibiotic therapy |
3 |
|
commencement |
3 |
|
complement c3 - biosynthesis - genetics |
3 |
|
complications |
3 |
|
conservative management |
3 |
|
corticosteroids |
3 |
|
covid‐19 |
3 |
|
creatinine - metabolism |
3 |
|
crescentic glomerulonephritis |
3 |
|
cyclosporins |
3 |
|
cytokines - analysis |
3 |
|
cytokines - biosynthesis - genetics |
3 |
|
cytokines - pharmacology |
3 |
|
delusions - chemically induced |
3 |
|
dematiaceous fungi |
3 |
|
dendrimer nanovector |
3 |
|
denver shunt |
3 |
|
depression |
3 |
|
diabetic nephropathies - complications - drug therapy |
3 |
|
diltiazem |
3 |
|
disease models, animal |
3 |
|
disease relapse |
3 |
|
disseminated ochroconis gallopavum |
3 |
|
diverticulosis |
3 |
|
diverticulosis, colonic - complications |
3 |
|
dna - genetics |
3 |
|
dna - immunology |
3 |
|
dna probes - diagnostic use |
3 |
|
dna, viral - genetics - isolation & purification |
3 |
|
doxorubicin - toxicity |
3 |
|
drug administration schedule |
3 |
|
drug resistance, microbial |
3 |
|
drug-induced liver injury - complications - etiology |
3 |
|
dyskinesia, drug-induced - etiology - therapy |
3 |
|
e coli |
3 |
|
emerging therapies |
3 |
|
emodin |
3 |
|
emodin - pharmacology |
3 |
|
emt |
3 |
|
enalapril - therapeutic use |
3 |
|
endemic diseases |
3 |
|
enhanced psychosocial support |
3 |
|
enteric peritonitis |
3 |
|
enzyme inhibitors - pharmacology |
3 |
|
enzyme inhibitors - therapeutic use |
3 |
|
epithelial cells - cytology |
3 |
|
epithelial cells - immunology |
3 |
|
epithelium - metabolism - pathology |
3 |
|
epr effect |
3 |
|
escherichia coli - enzymology |
3 |
|
escherichia coli infections |
3 |
|
estrogen replacement therapy |
3 |
|
ethics |
3 |
|
ethics, medical |
3 |
|
ethnic groups |
3 |
|
european continental ancestry group |
3 |
|
evaluation studies as topic |
3 |
|
exercise tolerance |
3 |
|
exhausted memory b cells |
3 |
|
exit-site infection |
3 |
|
extended-spectrum beta-lactamase |
3 |
|
face |
3 |
|
family |
3 |
|
far east |
3 |
|
fibroblast growth factor 2 - analysis |
3 |
|
fibronectins - biosynthesis - genetics |
3 |
|
fibrosis - etiology - metabolism |
3 |
|
flaviviridae infections - epidemiology |
3 |
|
fluorescent antibody technique |
3 |
|
focal segmental glomerulosclerosis |
3 |
|
fuel oils - poisoning |
3 |
|
gastric acid inhibitor |
3 |
|
gb virus c |
3 |
|
gene expression - drug effects - immunology |
3 |
|
gene frequency |
3 |
|
gene mutation |
3 |
|
genetic markers |
3 |
|
glomerular mesangium - pathology - ultrastructure |
3 |
|
glomerulonephritis, iga - complications - drug therapy |
3 |
|
glomerulonephritis, iga - etiology |
3 |
|
glomerulonephritis, iga - etiology - pathology |
3 |
|
glomerulonephritis, membranous - drug therapy - ethnology - metabolism |
3 |
|
glomerulonephritis, membranous - etiology - immunology |
3 |
|
glomerulosclerosis |
3 |
|
glomerulosclerosis, focal segmental - chemically induced - drug therapy - immunology |
3 |
|
glucocorticoids - adverse effects |
3 |
|
glucose - metabolism |
3 |
|
goodpasture's syndrome |
3 |
|
graft survival |
3 |
|
graft survival - physiology |
3 |
|
graft vs host disease - complications - etiology |
3 |
|
graft vs host disease - complications - immunology |
3 |
|
graft vs leukemia effect |
3 |
|
gram-negative bacterial infections - diagnosis - etiology - therapy |
3 |
|
gram-negative bacterial infections - drug therapy - etiology |
3 |
|
gram-positive bacterial infections - diagnosis - etiology - therapy |
3 |
|
granuloma - etiology |
3 |
|
guanine - analogs & derivatives - pharmacology - therapeutic use |
3 |
|
haematuria |
3 |
|
haplotypes - genetics |
3 |
|
helical ct angiography |
3 |
|
hematopoietic stem cell transplantation - adverse effects |
3 |
|
hematuria - etiology |
3 |
|
hemolysis |
3 |
|
hepacivirus - genetics |
3 |
|
hepatitis antibodies - analysis |
3 |
|
hepatitis b - diagnosis - virology |
3 |
|
hepatitis b - drug therapy |
3 |
|
hepatitis b - epidemiology - prevention & control |
3 |
|
hepatitis b antibodies - blood |
3 |
|
hepatitis b e antigens - blood |
3 |
|
hepatitis b surface antigens - immunology |
3 |
|
hepatitis b vaccine |
3 |
|
hepatitis b vaccines - administration & dosage - immunology |
3 |
|
hepatitis b virus - drug effects - genetics - isolation & purification |
3 |
|
hepatitis b virus - genetics - isolation & purification |
3 |
|
hepatitis b, chronic - epidemiology |
3 |
|
hepatitis c - drug therapy - etiology - virology |
3 |
|
hepatitis c antibodies |
3 |
|
hepatitis c, chronic - complications - drug therapy |
3 |
|
hepatitis c, chronic - epidemiology |
3 |
|
hepatitis c, chronic - epidemiology - mortality |
3 |
|
heptanoic acids - administration & dosage |
3 |
|
histones - immunology |
3 |
|
hong kong - ethnology |
3 |
|
hormonal replacement therapy |
3 |
|
hospital anxiety and depression scale (hads) |
3 |
|
hospital costs |
3 |
|
human peritoneal mesothelial cells |
3 |
|
hydrogen-ion concentration |
3 |
|
hydrothorax |
3 |
|
hydrothorax - etiology - therapy |
3 |
|
hyperbilirubinemia - complications - microbiology - therapy |
3 |
|
hyperleptinaemia |
3 |
|
hypertension |
3 |
|
hypogonadism - complications |
3 |
|
hysteroscopy - adverse effects |
3 |
|
immunization, secondary |
3 |
|
immunocompromised host - drug effects - immunology |
3 |
|
immunoglobulin a - metabolism - pharmacology |
3 |
|
immunoglobulin a, secretory - pharmacology |
3 |
|
immunoglobulin g |
3 |
|
immunoglobulin g - analysis - immunology - pharmacology |
3 |
|
immunoglobulin g - pharmacology |
3 |
|
immunoglobulins |
3 |
|
immunosuppressive agents - administration & dosage |
3 |
|
immunosuppressive agents - pharmacology - therapeutic use |
3 |
|
immunotherapy, adoptive - adverse effects |
3 |
|
in situ hybridization, fluorescence |
3 |
|
infant, newborn |
3 |
|
inflammation - blood - etiology |
3 |
|
injections, intradermal |
3 |
|
injections, intraperitoneal |
3 |
|
interferon-alpha - administration & dosage - adverse effects - therapeutic use |
3 |
|
interferon-alpha - adverse effects - therapeutic use |
3 |
|
interleukin 10 |
3 |
|
interleukin-1 (il-1) |
3 |
|
interleukin-1 - analysis |
3 |
|
interleukin-1 - blood |
3 |
|
interleukin-10 - genetics |
3 |
|
interleukin-2 - adverse effects |
3 |
|
interleukin-6 (il-6) |
3 |
|
interleukin-6 - analysis |
3 |
|
intracellular signaling peptides and proteins |
3 |
|
ischemia |
3 |
|
jaundice - complications - microbiology - therapy |
3 |
|
kdigo |
3 |
|
kidney - blood supply |
3 |
|
kidney - drug effects |
3 |
|
kidney - metabolism |
3 |
|
kidney - physiopathology |
3 |
|
kidney biopsy |
3 |
|
kidney diseases - pathology |
3 |
|
kidney failure, acute - microbiology |
3 |
|
kidney failure, chronic - blood - mortality - therapy |
3 |
|
kidney failure, chronic - complications |
3 |
|
kidney failure, chronic - complications - therapy |
3 |
|
kidney failure, chronic - diagnosis - therapy |
3 |
|
kidney failure, chronic - surgery |
3 |
|
kidney glomerulus - blood supply - chemistry - immunology |
3 |
|
kidney glomerulus - immunology - metabolism - pathology |
3 |
|
kidney transplant |
3 |
|
kidney transplantation - adverse effects - immunology - mortality |
3 |
|
kidney transplantation - ethics - methods |
3 |
|
kidney transplantation - methods - physiology |
3 |
|
kidney transplantation - mortality |
3 |
|
kidney tubules, proximal - metabolism |
3 |
|
killer cells, lymphokine-activated - transplantation |
3 |
|
kinetics |
3 |
|
kt/v |
3 |
|
ku70 |
3 |
|
lamivudine resistance |
3 |
|
leptin - blood |
3 |
|
leukemia, myelogenous, chronic, bcr-abl positive - therapy |
3 |
|
lipids - blood |
3 |
|
liver - enzymology |
3 |
|
liver cirrhosis - complications |
3 |
|
liver neoplasms - therapy |
3 |
|
liver transplantation - methods - physiology |
3 |
|
living donors - ethics - supply & distribution |
3 |
|
living renal donors |
3 |
|
living-related donor |
3 |
|
longitudinal studies |
3 |
|
lopinavir‐ritonavir |
3 |
|
losartan - therapeutic use |
3 |
|
lung - microbiology |
3 |
|
lung abscess - microbiology - radiography |
3 |
|
lupus erythematosus, systemic |
3 |
|
lupus erythematosus, systemic - complications - drug therapy - epidemiology - immunology |
3 |
|
lupus erythematosus, systemic - drug therapy |
3 |
|
lupus erythematosus, systemic - immunology |
3 |
|
lupus nephritis - drug therapy - pathology |
3 |
|
lupus nephritis - immunology - pathology - prevention & control |
3 |
|
lupus nephritis pathogenesis |
3 |
|
lupus pleuritis |
3 |
|
lymphocele |
3 |
|
lymphocyte |
3 |
|
lymphocyte transfusion - adverse effects |
3 |
|
lymphoproliferative disorders - etiology |
3 |
|
macrophages, peritoneal - chemistry |
3 |
|
macrophages, peritoneal - metabolism |
3 |
|
magnetic resonance imaging |
3 |
|
malnutrition |
3 |
|
mannose binding lectin |
3 |
|
mannose-binding lectin - genetics - metabolism |
3 |
|
mice, inbred nzb |
3 |
|
microscopy, electron |
3 |
|
minimal |
3 |
|
mir-200c |
3 |
|
mitogen-activated protein kinase (mapk) |
3 |
|
mitosporic fungi |
3 |
|
multiple renal arteries |
3 |
|
mutation |
3 |
|
mycobacterial infection |
3 |
|
mycobacterium tuberculosis - drug effects - isolation & purification |
3 |
|
mycobacterium tuberculosis - isolation & purification |
3 |
|
mycophenolic acid - analogs & derivatives - therapeutic use |
3 |
|
mycoses - drug therapy |
3 |
|
natural killer cell |
3 |
|
naval medicine |
3 |
|
nephrotic syndrome - etiology |
3 |
|
nitric oxide |
3 |
|
nod2 signaling adaptor protein |
3 |
|
non-steroidal anti-inflammatory drugs |
3 |
|
non-viral delivery |
3 |
|
nzb/w f1 mice |
3 |
|
obesity |
3 |
|
onychomycosis - etiology |
3 |
|
opportunistic infections - diagnosis - drug therapy |
3 |
|
optimal |
3 |
|
organ preservation |
3 |
|
osteonecrosis - diagnosis - epidemiology - etiology |
3 |
|
osteopenia |
3 |
|
osteoporosis |
3 |
|
osteoporosis - chemically induced - drug therapy - physiopathology |
3 |
|
outcome assessment (health care) |
3 |
|
pegylated interferon |
3 |
|
penicillanic acid - analogs & derivatives - therapeutic use |
3 |
|
penicillins - therapeutic use |
3 |
|
peritoneal dialysis - mortality |
3 |
|
peritoneal dialysis, continuous ambulatory - adverse effects - methods |
3 |
|
peritoneal dialysis, continuous ambulatory - statistics & numerical data |
3 |
|
peritoneal diseases - etiology - metabolism |
3 |
|
peritoneal transport |
3 |
|
peritoneum - metabolism - pathology |
3 |
|
peritonitis - blood - complications |
3 |
|
peritonitis - blood - etiology - metabolism |
3 |
|
peritonitis - blood - therapy |
3 |
|
peritonitis - drug therapy - epidemiology - prevention & control |
3 |
|
peritonitis - epidemiology - etiology |
3 |
|
peritonitis - etiology |
3 |
|
peritonitis - etiology - genetics - metabolism |
3 |
|
peritonitis - etiology - metabolism |
3 |
|
peritonitis - pathology |
3 |
|
peritonitis, tuberculous - complications - drug therapy - mortality |
3 |
|
peroxidase - immunology |
3 |
|
ph |
3 |
|
phosphonic acids - pharmacology - therapeutic use |
3 |
|
pichia |
3 |
|
plasma exchange |
3 |
|
pleura - immunology |
3 |
|
pleural diseases - immunology |
3 |
|
pleural mesothelial cells |
3 |
|
pleurodesis |
3 |
|
pleurodesis - methods |
3 |
|
point mutation |
3 |
|
polyethylene glycols - adverse effects - therapeutic use |
3 |
|
polymorphism |
3 |
|
postoperative complications - epidemiology |
3 |
|
postoperative complications - therapy |
3 |
|
postrenal transplant |
3 |
|
prednisolone - adverse effects |
3 |
|
pregnancy complications |
3 |
|
pregnancy outcome |
3 |
|
premenopause - drug effects - metabolism |
3 |
|
probability |
3 |
|
procalcitonin |
3 |
|
programmed cell death 1 receptor |
3 |
|
promoter regions, genetic - genetics |
3 |
|
protein precursors - blood - metabolism |
3 |
|
protein-energy malnutrition - diagnosis - etiology |
3 |
|
proteinuria - drug therapy |
3 |
|
proteinuria - metabolism |
3 |
|
psychological symptoms |
3 |
|
pulmonary hzemorrbage |
3 |
|
pyelonephritis - drug therapy |
3 |
|
pyrroles - administration & dosage |
3 |
|
quality of life (qol) |
3 |
|
ramipril - therapeutic use |
3 |
|
randomized controlled trial (rct) |
3 |
|
receptors, cell surface - genetics - metabolism |
3 |
|
receptors, fc - genetics - immunology - metabolism |
3 |
|
receptors, polymeric immunoglobulin - genetics - metabolism |
3 |
|
recombinant proteins - adverse effects |
3 |
|
renal allograft recipient |
3 |
|
renal arteriography |
3 |
|
renal artery - abnormalities - radiography |
3 |
|
renal artery - radiography |
3 |
|
renal artery obstruction - diagnosis - epidemiology - therapy |
3 |
|
renal biopsy |
3 |
|
renal cell carcinoma |
3 |
|
renal insufficiency, chronic |
3 |
|
renal transplant recipient |
3 |
|
reproducibility of results |
3 |
|
reverse transcriptase inhibitors - therapeutic use |
3 |
|
rhodococcus equi - isolation & purification |
3 |
|
ribavirin |
3 |
|
ribavirin - administration & dosage - adverse effects - therapeutic use |
3 |
|
rifampin - therapeutic use |
3 |
|
rna, messenger - genetics |
3 |
|
rna, viral - blood |
3 |
|
rnai therapy |
3 |
|
sampling studies |
3 |
|
sars‐cov‐2 |
3 |
|
seawater |
3 |
|
sex distribution |
3 |
|
shear wave elastography |
3 |
|
ships |
3 |
|
sirna delivery |
3 |
|
sirolimus - administration & dosage |
3 |
|
sirolimus - pharmacology - therapeutic use |
3 |
|
sirolimus - therapeutic use |
3 |
|
slimming |
3 |
|
social support |
3 |
|
social worker |
3 |
|
spleen - microbiology |
3 |
|
splenomegaly |
3 |
|
spousal donor |
3 |
|
spouses |
3 |
|
statistics, nonparametric |
3 |
|
steroids - adverse effects |
3 |
|
subsets |
3 |
|
survival analysis |
3 |
|
sweden |
3 |
|
systemic lupus erythematosis |
3 |
|
t-lymphocytes - immunology |
3 |
|
talc |
3 |
|
talc poudrage |
3 |
|
target |
3 |
|
targeted therapy |
3 |
|
terfenadine - adverse effects |
3 |
|
tgf-β1 |
3 |
|
tgfβ1 |
3 |
|
thienamycins - therapeutic use |
3 |
|
thoracoscopy - methods |
3 |
|
tinea - etiology |
3 |
|
tinea pedis - etiology |
3 |
|
tissue and organ harvesting |
3 |
|
tissue and organ procurement - organization & administration |
3 |
|
tomography, x-ray computed - economics - methods |
3 |
|
transferrin - metabolism - pharmacology |
3 |
|
transforming growth factor beta - analysis - genetics |
3 |
|
transforming growth factor beta - biosynthesis - genetics |
3 |
|
transforming growth factor beta1 |
3 |
|
transforming growth factor-β (tgf-β) |
3 |
|
transplant |
3 |
|
transplantation chimera - immunology |
3 |
|
transplantation immunology |
3 |
|
transplantation, homologous - immunology - mortality |
3 |
|
treatment failure |
3 |
|
treatment, infectious peritonitis |
3 |
|
trypan blue |
3 |
|
tuberculosis - complications - drug therapy - mortality |
3 |
|
tuberculosis - complications - epidemiology - immunology - prevention & control |
3 |
|
tuberculosis - diagnosis - drug therapy - epidemiology - etiology |
3 |
|
tuberculosis, lymph node - complications - drug therapy - mortality |
3 |
|
tuberculosis, pulmonary - complications - drug therapy - mortality |
3 |
|
tuberculous peritonitis |
3 |
|
tubulo-interstitial fibrosis |
3 |
|
tubulointerstitial disease |
3 |
|
tumor necrosis factor-alpha - blood |
3 |
|
ultrasonography |
3 |
|
uremia - metabolism - therapy |
3 |
|
urinary tract infection |
3 |
|
urinary tract infections - etiology - microbiology - therapy |
3 |
|
urothelium - metabolism |
3 |
|
vancomycin - therapeutic use |
3 |
|
vasculitis - immunology |
3 |
|
video recording |
3 |
|
viral load |
3 |
|
viral load - drug effects |
3 |
|
viremia - epidemiology - virology |
3 |
|
water pollutants, chemical - poisoning |
3 |
|
weil disease - complications - therapy |
3 |
|
young hypogonadal women |
3 |
|
25-hydroxyvitamin d |
2 |
|
aanti-gbm |
2 |
|
aav |
2 |
|
abo blood-group system - immunology |
2 |
|
abstracting, bibliographies, statistics medical sciences |
2 |
|
actin cytoskeleton - physiology |
2 |
|
actin cytoskeleton - ultrastructure |
2 |
|
actinin - metabolism |
2 |
|
acute kidney injury - complications - diagnosis - therapy |
2 |
|
acute kidney injury - diagnosis - etiology - therapy |
2 |
|
adequacy of dialysis |
2 |
|
adherence |
2 |
|
adrenal cortex hormones - adverse effects |
2 |
|
advanced ckd |
2 |
|
akt |
2 |
|
albuminuria |
2 |
|
alkaline phosphatase - blood |
2 |
|
alkaline phosphatase - metabolism |
2 |
|
allergen |
2 |
|
allergology and immunology medical sciences |
2 |
|
alloimmune hemolysis |
2 |
|
alternative pathway |
2 |
|
amikacin - administration & dosage - therapeutic use |
2 |
|
amino acid dialysate |
2 |
|
amino acid motifs |
2 |
|
amino acids |
2 |
|
amino acids - administration & dosage - therapeutic use |
2 |
|
amino acids - pharmacology |
2 |
|
ampicillin - administration & dosage - therapeutic use |
2 |
|
anaemia |
2 |
|
anc |
2 |
|
anca |
2 |
|
angiofollicular lymph node hyperplasia |
2 |
|
angiolymphoid hyperplasia with eosinophilia - complications |
2 |
|
annexin a2 - genetics - metabolism |
2 |
|
anti-arrhythmia agents - adverse effects |
2 |
|
anti-bacterial agents - administration & dosage - therapeutic use |
2 |
|
anti-dna antibodies |
2 |
|
anti-gbm |
2 |
|
anti-inflammatory agents - therapeutic use |
2 |
|
antibodies, anti-idiotypic - metabolism |
2 |
|
antibodies, antinuclear - blood - immunology |
2 |
|
antibodies, antinuclear - pharmacology |
2 |
|
antibodies, antinuclear - physiology |
2 |
|
antibodies, bacterial - blood |
2 |
|
antibodies, monoclonal - therapeutic use |
2 |
|
antibodies, viral - analysis |
2 |
|
antigen-antibody complex |
2 |
|
antigens, cd - analysis |
2 |
|
antigens, cd14 - blood |
2 |
|
antigens, cd2 - analysis |
2 |
|
antigens, cd3 - analysis |
2 |
|
antigens, cd56 - analysis |
2 |
|
antigens, viral - blood |
2 |
|
antigens, viral - blood - drug effects |
2 |
|
antiviral agents - administration & dosage - therapeutic use |
2 |
|
arteriovenous fistula/radiography |
2 |
|
arteriovenous fistula/therapy |
2 |
|
asia: health economics |
2 |
|
asian continental ancestry group - statistics & numerical data |
2 |
|
asian patients |
2 |
|
asymptomatic |
2 |
|
atorvastatin |
2 |
|
autoantigens - immunology |
2 |
|
autoimmune diseases |
2 |
|
automated peritoneal dialysis |
2 |
|
azathioprine - administration & dosage - adverse effects - economics |
2 |
|
b cell |
2 |
|
b cell abnormalities |
2 |
|
bicarbonate |
2 |
|
bicarbonates |
2 |
|
biglycan |
2 |
|
biochemistry abstracting and indexing services |
2 |
|
biocompatible materials |
2 |
|
biological assay - methods |
2 |
|
biological markers - metabolism |
2 |
|
biological transport |
2 |
|
biopsy, needle |
2 |
|
blood - immunology |
2 |
|
blood glucose - analysis |
2 |
|
blood preservation |
2 |
|
blood transfusion |
2 |
|
blotting, southern |
2 |
|
buffers |
2 |
|
c3 |
2 |
|
calcifediol |
2 |
|
calcineurine inhibitor |
2 |
|
canada |
2 |
|
carcinogens - pharmacology |
2 |
|
castleman's disease |
2 |
|
catheter implantation |
2 |
|
catheters |
2 |
|
cause of death |
2 |
|
cd14 |
2 |
|
cd4+t cells |
2 |
|
cd4-positive t-lymphocytes - immunology - metabolism |
2 |
|
cd40l |
2 |
|
cefazolin - therapeutic use |
2 |
|
cell adhesion molecules |
2 |
|
cell culture techniques |
2 |
|
cell differentiation |
2 |
|
cell differentiation - drug effects |
2 |
|
cell division - drug effects |
2 |
|
cell membrane permeability |
2 |
|
cell survival |
2 |
|
childhood-onset |
2 |
|
chinese population |
2 |
|
cholesterol - blood |
2 |
|
chromosomes, human, pair 16 |
2 |
|
chronic active hepatitis |
2 |
|
chronic microbial infections |
2 |
|
chronic renal failure |
2 |
|
classical pathway |
2 |
|
clinical outcome |
2 |
|
clinical outcomes |
2 |
|
clinical trial |
2 |
|
cmv dnaemia |
2 |
|
co-stimulatory molecules |
2 |
|
codon |
2 |
|
collagen type i - metabolism |
2 |
|
complement c3 - analysis |
2 |
|
complement system proteins - analysis |
2 |
|
computed tomographic peritoneography |
2 |
|
computerized tomographic peritoneography |
2 |
|
cost-benefit analysis |
2 |
|
creatinine clearance |
2 |
|
cyclic amp response element-binding protein - metabolism |
2 |
|
cyclophosphamide - administration & dosage - adverse effects - economics |
2 |
|
cyclosporine - adverse effects |
2 |
|
cystatin c |
2 |
|
cystatins - blood |
2 |
|
cytokeratin |
2 |
|
cytomegalovirus - drug effects - genetics - immunology - isolation & purification |
2 |
|
cytomegalovirus - genetics - isolation & purification |
2 |
|
cytomegalovirus infections - diagnosis |
2 |
|
cytomegalovirus infections - diagnosis - drug therapy - immunology - virology |
2 |
|
damage |
2 |
|
darbepoetin alpha |
2 |
|
decision trees |
2 |
|
demyelinating diseases - etiology - therapy |
2 |
|
demyelinating neuropathy |
2 |
|
device removal |
2 |
|
diabetic nephropathies - epidemiology |
2 |
|
diabetic nephropathies - surgery |
2 |
|
dialysis catheter insertion |
2 |
|
dialysis solutions |
2 |
|
dialysis solutions - administration & dosage - therapeutic use |
2 |
|
dialysis solutions - adverse effects |
2 |
|
dialysis solutions - chemistry - pharmacology |
2 |
|
diet |
2 |
|
disease progression |
2 |
|
dna - analysis - genetics |
2 |
|
dna methylation |
2 |
|
dna mutational analysis |
2 |
|
dna, viral |
2 |
|
dna, viral - analysis - blood |
2 |
|
dna, viral - genetics |
2 |
|
donor-derived |
2 |
|
donors |
2 |
|
drug costs - statistics & numerical data |
2 |
|
drug evaluation |
2 |
|
drug resistance |
2 |
|
dyslipidemias - drug therapy - epidemiology - etiology |
2 |
|
dyspepsia |
2 |
|
dyspepsia - epidemiology |
2 |
|
e4bp4 |
2 |
|
ebf1 |
2 |
|
electric impedance |
2 |
|
electron spin resonance spectroscopy - methods |
2 |
|
eosinophilia - drug therapy - etiology |
2 |
|
eosinophilic peritonitis |
2 |
|
epidermal cyst - etiology |
2 |
|
epidermoid cyst |
2 |
|
epigenetics |
2 |
|
epithelial cells - metabolism - pathology |
2 |
|
epithelial cells - metabolism - physiology |
2 |
|
epithelial cells - metabolism - secretion |
2 |
|
epithelial cells - physiology |
2 |
|
epithelial-to- mesenchymal transdifferentiation |
2 |
|
epithelial-to-mesenchymal transdifferentiation |
2 |
|
epithelium |
2 |
|
epstein syndrome |
2 |
|
equipment design |
2 |
|
erythropoiesis-stimulating agent |
2 |
|
erythropoietin |
2 |
|
everolimus |
2 |
|
exercise capacity |
2 |
|
exercise test - statistics & numerical data |
2 |
|
exercise therapy - statistics & numerical data |
2 |
|
exercise training |
2 |
|
exit site infection |
2 |
|
experimental medicine, laboratory technique |
2 |
|
extracellular matrix |
2 |
|
extracellular matrix proteins - metabolism |
2 |
|
extrapulmonary manifestation |
2 |
|
false negative reactions |
2 |
|
feasibility studies |
2 |
|
fibrillary |
2 |
|
fibronectins - biosynthesis |
2 |
|
fibronectins - metabolism |
2 |
|
focal adhesions - metabolism |
2 |
|
foxp3 |
2 |
|
foxp3 tsdr |
2 |
|
fruit - poisoning |
2 |
|
fungal peritonitis |
2 |
|
gamma-glutamyltransferase - metabolism |
2 |
|
ganciclovir - administration & dosage - therapeutic use |
2 |
|
gastrointestinal hemorrhage - diagnosis - etiology - therapy |
2 |
|
gender |
2 |
|
gene expression regulation |
2 |
|
giant lymph node hyperplasia - complications - drug therapy - pathology |
2 |
|
glomerular basement membrane - immunology |
2 |
|
glomerular mesangium - immunology |
2 |
|
glomerular mesangium - metabolism |
2 |
|
glomerular mesangium - pathology |
2 |
|
glomerulonephritis - classification - epidemiology - surgery |
2 |
|
glomerulonephritis - complications - immunology |
2 |
|
glomerulonephritis - diagnosis - genetics |
2 |
|
glomerulonephritis - pathology |
2 |
|
glomerulonephritis, iga - complications - physiopathology - prevention & control |
2 |
|
glomerulonephritis, iga - diagnosis - immunology - pathology - therapy |
2 |
|
glomerulonephritis, iga - epidemiology |
2 |
|
glomerulonephritis, iga - pathology |
2 |
|
glomerulonephritis, iga - surgery |
2 |
|
glomerulonephritis, membranoproliferative - complications - drug therapy - pathology |
2 |
|
glomerulonephritis, membranoproliferative - surgery |
2 |
|
glomerulonephritis, membranous - surgery |
2 |
|
glomerulonephropathy |
2 |
|
glomerulosclerosis, focal segmental - surgery |
2 |
|
glucans |
2 |
|
glucose transport |
2 |
|
glucuronosyltransferase - genetics |
2 |
|
glycocalyx |
2 |
|
glycosaminoglycans |
2 |
|
glycosaminoglycans - biosynthesis - physiology |
2 |
|
glycosaminoglycans - metabolism |
2 |
|
graft rejection - epidemiology |
2 |
|
graft rejection - genetics - immunology |
2 |
|
graft rejection - physiopathology |
2 |
|
graft survival - drug effects |
2 |
|
gross haematuria |
2 |
|
gut microbiota |
2 |
|
has-mir-1246 |
2 |
|
hcv genotype |
2 |
|
hcv rna |
2 |
|
hearing loss, sensorineural - diagnosis - genetics |
2 |
|
heavy chain disease - diagnosis - immunology - pathology - therapy |
2 |
|
helicobacter infections - epidemiology |
2 |
|
helicobacter pylori |
2 |
|
helicobacter pylori - immunology - isolation & purification |
2 |
|
hematoma - diagnosis - etiology - therapy |
2 |
|
hemodialysis solutions |
2 |
|
hemolysis - immunology |
2 |
|
hemoperitoneum |
2 |
|
hemoperitoneum - etiology - mortality - therapy |
2 |
|
hepacivirus - immunology |
2 |
|
heparan sulfate proteoglycans - biosynthesis |
2 |
|
heparin |
2 |
|
hepatitis - virology |
2 |
|
hepatitis antibodies - blood |
2 |
|
hepatitis b - blood - diagnosis - virology |
2 |
|
hepatitis b - diagnosis |
2 |
|
hepatitis b - drug therapy - epidemiology |
2 |
|
hepatitis b - drug therapy - prevention & control |
2 |
|
hepatitis b - etiology |
2 |
|
hepatitis b surface antigens - genetics |
2 |
|
hepatitis b virus - metabolism |
2 |
|
hepatitis c - enzymology - immunology - surgery |
2 |
|
hepatitis c - etiology - metabolism - pathology |
2 |
|
hepatitis c - etiology - therapy |
2 |
|
hepatitis c virus |
2 |
|
hepatitis c virus (hcv) |
2 |
|
hepatitis, chronic - etiology - metabolism - pathology |
2 |
|
herpesvirus 4, human - genetics |
2 |
|
histamine h1 antagonists - therapeutic use |
2 |
|
histone modification |
2 |
|
histone modifications |
2 |
|
hla antigens - genetics - immunology |
2 |
|
hmgb1 protein - genetics - metabolism |
2 |
|
hormone |
2 |
|
hospital costs - statistics & numerical data |
2 |
|
hrm-pcr |
2 |
|
human leukocyte antigen (hla) typing |
2 |
|
human mesangial cells |
2 |
|
hyaluronan synthase |
2 |
|
hyaluronic acid - biosynthesis |
2 |
|
hyaluronic acid - metabolism - secretion |
2 |
|
hydroxychloroquine |
2 |
|
hypercholesterolemia |
2 |
|
hyperlipidemia |
2 |
|
hyperlipidemias - complications - epidemiology |
2 |
|
hyperphosphataemia |
2 |
|
hypoalbuminemia - drug therapy - etiology |
2 |
|
hypocalcaemia |
2 |
|
icaritin |
2 |
|
il-1b |
2 |
|
il17a |
2 |
|
immunoglobulin |
2 |
|
immunoglobulin a |
2 |
|
immunoglobulin alpha-chains - analysis |
2 |
|
immunoglobulin g - immunology |
2 |
|
immunoglobulin m |
2 |
|
immunoglobulin m - analysis |
2 |
|
immunology |
2 |
|
immunophenotyping |
2 |
|
immunosuppressive agents - administration & dosage - adverse effects - economics |
2 |
|
income |
2 |
|
infection - economics - epidemiology - etiology |
2 |
|
inflammation - etiology |
2 |
|
inflammation - metabolism |
2 |
|
inflammation - physiopathology |
2 |
|
infusions, parenteral |
2 |
|
integrins |
2 |
|
interferon-alpha - therapeutic use |
2 |
|
interleukin-1 - physiology |
2 |
|
interleukin-10 |
2 |
|
interleukin-10 - biosynthesis |
2 |
|
interleukin-6 |
2 |
|
interleukin-6 - biosynthesis |
2 |
|
interleukin-6 - metabolism |
2 |
|
intracellular |
2 |
|
ischaemia-reperfusion injury |
2 |
|
ischemia - genetics - metabolism |
2 |
|
ischemia - physiopathology |
2 |
|
isoantibodies - blood |
2 |
|
itraconazole |
2 |
|
japan |
2 |
|
ketotifen |
2 |
|
ketotifen - therapeutic use |
2 |
|
kidney - blood supply - drug effects |
2 |
|
kidney - drug effects - metabolism - pathology |
2 |
|
kidney - immunology - physiopathology |
2 |
|
kidney diseases - chemically induced |
2 |
|
kidney diseases - diagnosis - etiology - therapy |
2 |
|
kidney diseases - etiology - therapy |
2 |
|
kidney diseases - metabolism - physiopathology |
2 |
|
kidney diseases/pathology |
2 |
|
kidney failure, chronic - blood - complications - therapy |
2 |
|
kidney failure, chronic - economics - epidemiology - therapy |
2 |
|
kidney failure, chronic - epidemiology - therapy |
2 |
|
kidney failure, chronic - etiology |
2 |
|
kidney failure, chronic - etiology - mortality |
2 |
|
kidney failure, chronic - etiology - physiopathology - surgery |
2 |
|
kidney failure, chronic - immunology - surgery - virology |
2 |
|
kidney function tests |
2 |
|
kidney glomerulus - chemistry - pathology |
2 |
|
kidney glomerulus - pathology |
2 |
|
kidney transplantation - adverse effects - immunology |
2 |
|
kidney transplantation - methods |
2 |
|
kidney tubules, proximal - cytology - metabolism |
2 |
|
kidney, polycystic/genetics |
2 |
|
killer cells, natural - immunology |
2 |
|
lamivudine - administration & dosage |
2 |
|
lamivudine - pharmacology |
2 |
|
lectins, c-type |
2 |
|
leukemia, t-cell - diagnosis - immunology - virology |
2 |
|
leukocytes - virology |
2 |
|
linkage (genetics) |
2 |
|
lipopolysaccharide |
2 |
|
lipopolysaccharide binding protein |
2 |
|
listeriosis - etiology |
2 |
|
liver - enzymology - pathology |
2 |
|
liver diseases - enzymology - pathology |
2 |
|
liver diseases - immunology |
2 |
|
liver failure |
2 |
|
liver function tests |
2 |
|
living-related donors |
2 |
|
longterm treatment |
2 |
|
lupus erythematosus, systemic - blood - immunology |
2 |
|
lupus erythematosus, systemic - genetics - immunology - metabolism |
2 |
|
lupus erythematosus, systemic - immunology - pathology |
2 |
|
lupus erythematosus, systemic - surgery |
2 |
|
lupus nephritis - blood - classification - complications - drug therapy - pathology |
2 |
|
lupus nephritis - blood - complications |
2 |
|
lupus nephritis - classification - drug therapy |
2 |
|
lupus nephritis - complications |
2 |
|
lupus nephritis - complications - mortality |
2 |
|
lupus nephritis - drug therapy - economics - epidemiology |
2 |
|
lupus nephritis - drug therapy - metabolism - pathology |
2 |
|
lupus nephritis - drug therapy - physiopathology |
2 |
|
lupus nephritis - etiology - metabolism |
2 |
|
lupus nephritis - immunology - physiopathology |
2 |
|
lupus nephritis - metabolism - pathology |
2 |
|
lupus nephritis - pathology |
2 |
|
lupus nephritis - therapy |
2 |
|
lymphadenitis |
2 |
|
lymphocytes - immunology |
2 |
|
magnetic resonance peritoneography |
2 |
|
maintenance immunosuppression |
2 |
|
malignancy |
2 |
|
malnutrition - etiology - therapy |
2 |
|
mammalian target of rapamycin |
2 |
|
mannose-binding lectin pathway |
2 |
|
mcns |
2 |
|
mediastinum |
2 |
|
medical records |
2 |
|
medical sciences medical sciences |
2 |
|
membrane glycoproteins - analysis |
2 |
|
membrane glycoproteins - genetics - metabolism |
2 |
|
membrane potentials |
2 |
|
membranoproliferative glomerulonephritis |
2 |
|
membranous |
2 |
|
men |
2 |
|
mesangial cells - metabolism - pathology |
2 |
|
mesothelial cell |
2 |
|
metalloproteinases |
2 |
|
methoxy polyethylene glycol-epoetin beta |
2 |
|
methylprednisolone |
2 |
|
microrna |
2 |
|
micrornas |
2 |
|
microvilli |
2 |
|
minimal change nephrotic syndrome |
2 |
|
mismatched human leukocyte antigens |
2 |
|
monocyte |
2 |
|
monocytes - metabolism |
2 |
|
mycobacterium infections - epidemiology - prevention & control |
2 |
|
mycophenolic acid - administration & dosage - adverse effects - analogs & derivatives - economics |
2 |
|
mycophenolic acid - analogs and derivatives - pharmacology - therapeutic use |
2 |
|
mycoses - diagnosis - etiology |
2 |
|
myosin heavy chains - genetics |
2 |
|
natural killer cell lymphoma |
2 |
|
neck |
2 |
|
nephrectomy |
2 |
|
nephrosis, lipoid - drug therapy - pathology |
2 |
|
nephrotic syndrome - complications |
2 |
|
neurotoxicity syndromes - etiology |
2 |
|
neurotoxins - adverse effects |
2 |
|
ng-nitroarginine methyl ester - pharmacology |
2 |
|
nitric oxide - analysis - biosynthesis |
2 |
|
nitric oxide - biosynthesis |
2 |
|
nitric oxide synthase - antagonists & inhibitors |
2 |
|
nitric oxide synthase - genetics |
2 |
|
nitric oxide synthase type ii |
2 |
|
nk cell lectin-like receptor subfamily d |
2 |
|
nuclear family |
2 |
|
nucleic acid hybridization |
2 |
|
nutrineal |
2 |
|
omentum |
2 |
|
osps |
2 |
|
p53 |
2 |
|
pain |
2 |
|
passenger lymphocyte |
2 |
|
pcr test |
2 |
|
penicillium - isolation & purification |
2 |
|
penicillium marneffei |
2 |
|
perinephric hematoma |
2 |
|
periodicity |
2 |
|
peritoneal dialysis (pd) |
2 |
|
peritoneal dialysis - economics - statistics & numerical data - utilization |
2 |
|
peritoneal dialysis - instrumentation |
2 |
|
peritoneal dialysis fluids |
2 |
|
peritoneal dialysis, continuous ambulatory - mortality - standards |
2 |
|
peritoneal dialysis, continuous ambulatory - utilization |
2 |
|
peritoneal diseases - metabolism |
2 |
|
peritoneal eosinophilia |
2 |
|
peritoneal fibroblasts |
2 |
|
peritoneal fibrosis |
2 |
|
peritoneal fibrosis - etiology - prevention & control |
2 |
|
peritoneal transport characteristics |
2 |
|
peritoneum - cytology - drug effects |
2 |
|
peritoneum - cytology - drug effects - metabolism |
2 |
|
peritoneum - cytology - metabolism - physiology |
2 |
|
peritoneum - drug effects |
2 |
|
peritoneum - metabolism |
2 |
|
peritoneum - metabolism - physiopathology |
2 |
|
peritoneum - pathology |
2 |
|
peritoneum - pathology - physiology |
2 |
|
peritoneum - radiography |
2 |
|
peritonitis - blood - etiology - physiopathology |
2 |
|
peritonitis - drug therapy - etiology |
2 |
|
peritonitis - drug therapy - etiology - microbiology |
2 |
|
peritonitis - etiology - metabolism - pathology |
2 |
|
perlecan |
2 |
|
ph neutral |
2 |
|
phosphoproteins - blood |
2 |
|
phosphorylation - drug effects |
2 |
|
physical rehabilitation |
2 |
|
pkc |
2 |
|
plant poisoning - complications - diagnosis - mortality |
2 |
|
pneumonia - economics - epidemiology - etiology |
2 |
|
polyarteritis nodosa |
2 |
|
polyarteritis nodosa - complications - diagnosis |
2 |
|
polyester filter |
2 |
|
polyradiculoneuropathy, chronic inflammatory demyelinating - etiology |
2 |
|
post-transplantation |
2 |
|
postoperative complications |
2 |
|
postoperative complications - classification - epidemiology - prevention & control |
2 |
|
postoperative complications - drug therapy - virology |
2 |
|
postoperative complications - epidemiology - prevention & control |
2 |
|
postoperative complications - etiology - immunology |
2 |
|
postoperative complications - immunology |
2 |
|
pp65 assay |
2 |
|
prednisolone - administration & dosage |
2 |
|
preemptive treatment |
2 |
|
primary membranous nephropathy |
2 |
|
proliferation |
2 |
|
proliferation signal inhibitor |
2 |
|
proliferative lupus nephritis |
2 |
|
protein binding |
2 |
|
protein kinase c - metabolism |
2 |
|
protein kinase c-alpha |
2 |
|
protein-tyrosine kinases - metabolism |
2 |
|
proteoglycans |
2 |
|
proteoglycans - biosynthesis |
2 |
|
proteoglycans - biosynthesis - physiology |
2 |
|
proteoglycans - genetics - metabolism |
2 |
|
proteoglycans - metabolism |
2 |
|
psoriasis |
2 |
|
pyruvaldehyde - metabolism - toxicity |
2 |
|
randomized controlled trial |
2 |
|
receiver operating characteristic |
2 |
|
recombinant fusion proteins |
2 |
|
recovery of function |
2 |
|
recurrence - prevention & control |
2 |
|
regulatory t cells |
2 |
|
remission induction |
2 |
|
renal circulation |
2 |
|
renal fibrosis |
2 |
|
renal insufficiency - blood - diagnosis |
2 |
|
renal insufficiency - diagnosis - genetics - surgery |
2 |
|
renal insufficiency - immunology - physiopathology |
2 |
|
renal survival |
2 |
|
reoperation |
2 |
|
reperfusion injury - genetics - metabolism |
2 |
|
reperfusion injury - physiopathology |
2 |
|
residual renal function |
2 |
|
responsiveness |
2 |
|
retreatment |
2 |
|
retroperitoneal leakage |
2 |
|
retroperitoneal space |
2 |
|
reverse transcriptase inhibitors - administration & dosage |
2 |
|
reverse transcriptase inhibitors - pharmacology |
2 |
|
rheumatology |
2 |
|
rheumatology biology |
2 |
|
senescence |
2 |
|
seroepidemiologic studies |
2 |
|
serological reactivation |
2 |
|
serology |
2 |
|
serratia |
2 |
|
serum creatinine |
2 |
|
sex |
2 |
|
sex characteristics |
2 |
|
signal transduction |
2 |
|
simvastatin |
2 |
|
skin diseases - etiology |
2 |
|
socioeconomic factors |
2 |
|
sotalol - adverse effects |
2 |
|
stem cells |
2 |
|
sulbactam - administration & dosage - therapeutic use |
2 |
|
sulfur radioisotopes - diagnostic use |
2 |
|
symptom |
2 |
|
syndecan |
2 |
|
syndecan-4 |
2 |
|
t cells |
2 |
|
tacrolimus - adverse effects - therapeutic use |
2 |
|
takayasu arteritis - epidemiology |
2 |
|
telbivudine |
2 |
|
tenckhoff catheter insertion |
2 |
|
tetradecanoylphorbol acetate - pharmacology |
2 |
|
thrombocytopenia |
2 |
|
thrombocytopenia - diagnosis - genetics |
2 |
|
thrombospondin 1 - drug effects - genetics - physiology |
2 |
|
thrombotic microangiopathy |
2 |
|
tlr2 |
2 |
|
tobramycin - therapeutic use |
2 |
|
torsades de pointes - chemically induced |
2 |
|
transcriptome |
2 |
|
transforming growth factor beta - metabolism |
2 |
|
transforming growth factor beta - metabolism - secretion |
2 |
|
transforming growth factor beta1 - metabolism |
2 |
|
transforming growth factor-β1 |
2 |
|
transplantation immunology - immunology |
2 |
|
transplantation, homologous - adverse effects |
2 |
|
triple incision method |
2 |
|
trombospondin-1 |
2 |
|
tuberculosis - diagnosis - drug therapy |
2 |
|
tuberculosis - prevention & control |
2 |
|
tuberculosis, lymph node - diagnosis - etiology |
2 |
|
ultrafiltration failure |
2 |
|
united states |
2 |
|
urea - metabolism |
2 |
|
uremia |
2 |
|
uremia - complications - diagnosis - mortality - therapy |
2 |
|
urine |
2 |
|
urology and nephrology medical sciences |
2 |
|
vasculopathy |
2 |
|
vimentin |
2 |
|
viral matrix proteins - blood |
2 |
|
virus activation |
2 |
|
virus replication - drug effects |
2 |
|
vitamin d deficiency |
2 |
|
whole blood |
2 |
|
young adult |
2 |
|
α heavy chain |
2 |
|
24-hour urine protein |
1 |
|
activities of daily living |
1 |
|
activity |
1 |
|
acute pulmonary edema |
1 |
|
adenocarcinoma - etiology - secondary |
1 |
|
adhesion molecule |
1 |
|
adrenal cortex hormones - administration & dosage |
1 |
|
adrenal insufficiency |
1 |
|
albuminuria - epidemiology - ethnology - physiopathology - urine |
1 |
|
allograft kidney thrombosis |
1 |
|
allograft rupture |
1 |
|
amenorrhea - chemically induced |
1 |
|
anemia |
1 |
|
anemia - therapy |
1 |
|
anti-dna antibody |
1 |
|
anti-infective agents - administration & dosage - therapeutic use |
1 |
|
anti-inflammatory agents - administration & dosage |
1 |
|
anti-inflammatory agents - adverse effects - pharmacology |
1 |
|
anti-neutrophil cytoplasm antibody |
1 |
|
antibodies |
1 |
|
antibodies, antinuclear - biosynthesis - blood |
1 |
|
antibody formation |
1 |
|
anticoagulants - therapeutic use |
1 |
|
anticoagulation |
1 |
|
antifungal agents - administration & dosage |
1 |
|
antigens, viral - immunology |
1 |
|
antilymphocyte serum - blood |
1 |
|
antiphospholipid |
1 |
|
arthritis |
1 |
|
asia - epidemiology |
1 |
|
autoantibodies - biosynthesis - blood |
1 |
|
azathioprine - adverse effects - pharmacology |
1 |
|
bacterial infections - etiology |
1 |
|
blood pressure - physiology |
1 |
|
blood transfusion - adverse effects |
1 |
|
body mass index |
1 |
|
bone density |
1 |
|
bone mineral density (bmd) |
1 |
|
candida |
1 |
|
candidal peritonitis |
1 |
|
candidiasis - drug therapy - etiology |
1 |
|
candidiasis - etiology - prevention & control |
1 |
|
cardiovascular diseases - epidemiology - ethnology - physiopathology - urine |
1 |
|
catheterization - adverse effects |
1 |
|
cd4+ t cells |
1 |
|
child |
1 |
|
cholesterol |
1 |
|
cholesterol, ldl - blood |
1 |
|
chronic hepatitis |
1 |
|
chronic hepatitis c |
1 |
|
chronicity |
1 |
|
clinical nephrology |
1 |
|
clinical trials as topic |
1 |
|
cognitive defect |
1 |
|
cohort analysis |
1 |
|
congresses as topic |
1 |
|
continuous renal replacement therapy |
1 |
|
cost-effective analysis |
1 |
|
cost-effectiveness analysis |
1 |
|
costs and cost analysis |
1 |
|
cranial neuropathy |
1 |
|
creatinine - metabolism - urine |
1 |
|
creatinine - urine |
1 |
|
creatinine blood level |
1 |
|
crescentic lesions |
1 |
|
cyclophosphamide - administration & dosage |
1 |
|
cyclophosphamide - adverse effects - pharmacology |
1 |
|
cyclosporin neoral® |
1 |
|
cyclosporine - metabolism |
1 |
|
cyclosporine a |
1 |
|
cyclosporine/therapeutic use |
1 |
|
cytopenia |
1 |
|
data base |
1 |
|
delphi study |
1 |
|
deoxyribonucleases - metabolism - pharmacology |
1 |
|
diabetes mellitus, type 2 - complications - ethnology - physiopathology - urine |
1 |
|
diabetic nephropathies - epidemiology - ethnology - physiopathology - urine |
1 |
|
disease classification |
1 |
|
disease course |
1 |
|
diuresis |
1 |
|
dna - immunology - metabolism |
1 |
|
dna, viral - isolation & purification |
1 |
|
dosage conservation |
1 |
|
double therapy |
1 |
|
double-blind randomized trial |
1 |
|
drug administration routes |
1 |
|
end-stage kidney disease |
1 |
|
end-stage renal failure |
1 |
|
endothelial cell |
1 |
|
endothelium, vascular - immunology |
1 |
|
endothelium, vascular - immunology - metabolism |
1 |
|
enti-dna antibody |
1 |
|
erythropoietin - adverse effects |
1 |
|
eskd |
1 |
|
ethnicity |
1 |
|
fatigue - etiology - prevention & control |
1 |
|
first-dose reaction |
1 |
|
fluconazole |
1 |
|
fluconazole - therapeutic use |
1 |
|
fluorescent antibody technique, indirect |
1 |
|
gemfibrozil |
1 |
|
gemfibrozil - therapeutic use |
1 |
|
gentamicins - administration & dosage - therapeutic use |
1 |
|
global |
1 |
|
glucocorticoids |
1 |
|
graft rejection - complications - drug therapy - physiopathology |
1 |
|
gram-negative bacterial infections - drug therapy |
1 |
|
gram-positive bacterial infections - drug therapy |
1 |
|
hdl-cholesterol |
1 |
|
health education - methods |
1 |
|
hematoma - etiology |
1 |
|
hemoglobin a, glycosylated - metabolism |
1 |
|
hemoglobins |
1 |
|
hepacivirus - genetics - immunology |
1 |
|
hepatitis b - blood - diagnosis |
1 |
|
hepatitis b - epidemiology |
1 |
|
hepatitis b - prevention & control |
1 |
|
hepatitis b antigens - analysis |
1 |
|
hepatitis b surface antigens - analysis |
1 |
|
hepatitis b surface antigens - analysis - blood |
1 |
|
hepatitis b virus - isolation & purification |
1 |
|
hepatitis c - diagnosis - epidemiology |
1 |
|
hepatitis c - enzymology - genetics - therapy |
1 |
|
hepatitis c - epidemiology - etiology |
1 |
|
hepatitis c - epidemiology - etiology - immunology |
1 |
|
hepatitis c - epidemiology - immunology - microbiology |
1 |
|
hepatitis c - immunology - transmission |
1 |
|
hepatitis c - microbiology |
1 |
|
hepatitis, viral, human - drug therapy - epidemiology - prevention & control |
1 |
|
hepatitis/diagnosis |
1 |
|
hiv seropositivity |
1 |
|
hospitalization - statistics & numerical data |
1 |
|
hyperlipidemias - blood - drug therapy - etiology |
1 |
|
hypoadrenalism |
1 |
|
immune suppression |
1 |
|
immune tolerance |
1 |
|
immunocompetence |
1 |
|
immunoglobulin g - blood |
1 |
|
immunosuppressive agents - adverse effects - pharmacology |
1 |
|
immunosuppressive agents - metabolism |
1 |
|
immunosuppressive therapy |
1 |
|
infarction - drug therapy - etiology |
1 |
|
infection - chemically induced |
1 |
|
infections |
1 |
|
injections, intravenous |
1 |
|
integrated care |
1 |
|
intensive care |
1 |
|
interferons - therapeutic use |
1 |
|
international cooperation |
1 |
|
kidney - drug effects - pathology |
1 |
|
kidney diseases - etiology - physiopathology - surgery |
1 |
|
kidney failure |
1 |
|
kidney failure, chronic - metabolism - mortality - therapy |
1 |
|
kidney failure, chronic - prevention & control |
1 |
|
kidney transplantation - pathology - physiology |
1 |
|
kidney transplantation - statistics & numerical data |
1 |
|
kidney transplantation - statistics & numerical data - trends |
1 |
|
ldl-cholesterol |
1 |
|
leukemia - surgery |
1 |
|
leukocytes - immunology - virology |
1 |
|
levofloxacin |
1 |
|
life tables |
1 |
|
liver transplantation - statistics & numerical data |
1 |
|
lung neoplasms - complications - secondary |
1 |
|
lupus erythematosus, systemic - blood - epidemiology - immunology |
1 |
|
lupus nephritis - classification - pathology |
1 |
|
lupus nephritis - drug therapy - ethnology - mortality |
1 |
|
lupus nephritis - drug therapy - pathology - psychology |
1 |
|
megestrol acetate |
1 |
|
membrane proteins - metabolism |
1 |
|
meta-analysis |
1 |
|
methylprednisolone - adverse effects - pharmacology |
1 |
|
methylprednisolone - therapeutic use |
1 |
|
miconazole - therapeutic use |
1 |
|
mycophenolic acid - administration & dosage - analogs & derivatives |
1 |
|
mycophenonate mofetil |
1 |
|
mycoses - drug therapy - etiology |
1 |
|
mycoses - drug therapy - etiology - prevention & control |
1 |
|
myelopathy |
1 |
|
naphthalenes - therapeutic use |
1 |
|
netilmicin - administration & dosage - therapeutic use |
1 |
|
netromycin |
1 |
|
neurocognitive disorder |
1 |
|
neutrophil gelatinase-associated lipocalin |
1 |
|
nocardia infections - drug therapy - etiology |
1 |
|
nucleic acid hybridization - methods |
1 |
|
nutrition |
1 |
|
nutrition assessment |
1 |
|
nutritional status |
1 |
|
nystatin |
1 |
|
nystatin - administration & dosage |
1 |
|
o-set |
1 |
|
ofloxacin |
1 |
|
ofloxacin - administration & dosage - therapeutic use |
1 |
|
okt3 |
1 |
|
onychomycosis - drug therapy |
1 |
|
parathyroid hormone - blood |
1 |
|
pathophysiology |
1 |
|
patient acceptance of health care |
1 |
|
peliosis |
1 |
|
peritoneal dialysis - statistics & numerical data |
1 |
|
peritoneal dialysis, continuous ambulatory - adverse effects - economics - methods |
1 |
|
peritoneal dialysis, continuous ambulatory - mortality |
1 |
|
peritoneal dialysis, continuous ambulatory - mortality - statistics & numerical data |
1 |
|
peritoneal dialysis-related peritonitis |
1 |
|
peritonitis - drug therapy - etiology - prevention & control |
1 |
|
peritonitis - etiology - prevention & control |
1 |
|
peritonitis, tuberculous - drug therapy - etiology - mortality |
1 |
|
polyarteritis |
1 |
|
postoperative complications - epidemiology - virology |
1 |
|
postoperative complications - prevention & control - virology |
1 |
|
prednisolone |
1 |
|
prednisone - adverse effects - pharmacology |
1 |
|
prophylaxis |
1 |
|
proportional hazards models |
1 |
|
pulmonary embolism - etiology |
1 |
|
registries |
1 |
|
rejection |
1 |
|
remission |
1 |
|
renal artery - pathology |
1 |
|
rescue therapy |
1 |
|
rheumatoid arthritis |
1 |
|
rna |
1 |
|
roxadustat |
1 |
|
rupture, spontaneous |
1 |
|
segmental |
1 |
|
sepsis |
1 |
|
serum albumin - metabolism |
1 |
|
sf36 |
1 |
|
spleen |
1 |
|
splenic diseases - etiology |
1 |
|
stomach neoplasms - etiology - pathology |
1 |
|
surrogate end point |
1 |
|
sustainable care |
1 |
|
taiwan - epidemiology |
1 |
|
thromboembolism |
1 |
|
thromboembolism - drug therapy - etiology |
1 |
|
tissue and organ procurement - methods |
1 |
|
tissue donors - supply & distribution |
1 |
|
transforming growth factor-beta/metabolism |
1 |
|
transfusion |
1 |
|
transverse myelitis |
1 |
|
trichosporon |
1 |
|
triglyceride |
1 |
|
triglycerides - blood |
1 |
|
trimethoprim-sulfamethoxazole combination - therapeutic use |
1 |
|
triple therapy |
1 |
|
u-scd163 |
1 |
|
united states - epidemiology |
1 |
|
universal health care |
1 |
|
uremia - therapy |
1 |
|
urine protein-to-creatinine ratio |
1 |
|
uvxd |
1 |
|
vancomycin |
1 |
|
vancomycin - administration & dosage - therapeutic use |
1 |
|
viral core proteins - immunology |
1 |
|
viral envelope proteins - immunology |
1 |
|
viral nonstructural proteins - immunology |
1 |
|
viral/analysis |
1 |
|
virtual reality |
1 |
|
von willebrand factor |
1 |
|
wegener's granulomatosis |
1 |
|
whoqol |
1 |
